inclusion criteria: * 1. participant is willing and able to give written informed consent for participation in the trial. * 2. male or female, aged 18 years or above and in good health as determined by a trial clinician. * 3. female participants of childbearing potential must be willing to ensure that they or their partner use effective contraception from 1 month prior to first immunisation continuously until 3 months after boost immunisation. see section "contraception and pregnancy" for definition of child-bearing potential and definition of effective contraception. * 4. in the investigator's opinion, is able and willing to comply with all trial requirements. * 5. willing to allow investigators to discuss the volunteer's medical history with their general practitioner and access all medical records when relevant to study procedures. * 6. agreement to refrain from blood donation during the study. * 7. participants who have completed homologous primary vaccination with either inactivated or mrna or viral vector covid-19 vaccines (full approval, cma or eua) and is at least 6 months post second vaccination.

inclusion criteria: * 1. participant is willing and able to give written informed consent for participation in the trial. * 2. male or female, aged 18 years or above and in good health as determined by a trial clinician. * 3. female participants of childbearing potential must be willing to ensure that they or their partner use effective contraception from 1 month prior to first immunisation continuously until 3 months after boost immunisation. see section "contraception and pregnancy" for definition of child-bearing potential and definition of effective contraception. * 4. in the investigator's opinion, is able and willing to comply with all trial requirements. * 5. willing to allow investigators to discuss the volunteer's medical history with their general practitioner and access all medical records when relevant to study procedures. * 6. agreement to refrain from blood donation during the study. * 7. participants who have completed homologous primary vaccination with either inactivated or mrna or viral vector covid-19 vaccines (full approval, cma or eua) and is at least 6 months post second vaccination.

inclusion criteria: 1. participant is willing and able to give written informed consent for participation in the trial. 2. male or female, aged 18 years or above and in good health as determined by a trial clinician. 3. female participants of childbearing potential must be willing to ensure that they or their partner use effective contraception from 1 month prior to first immunisation continuously until 3 months after boost immunisation. see section "contraception and pregnancy" for definition of child-bearing potential and definition of effective contraception. 4. in the investigator's opinion, is able and willing to comply with all trial requirements. 5. willing to allow investigators to discuss the volunteer's medical history with their general practitioner and access all medical records when relevant to study procedures. 6. agreement to refrain from blood donation during the study. 7. participants who have completed homologous primary vaccination with either inactivated or mrna or viral vector covid-19 vaccines (full approval, cma or eua) and is at least 6 months post second vaccination.

inclusion criteria: 1. participant is willing and able to give written informed consent for participation in the trial. 2. male or female, aged 18 years or above and in good health as determined by a trial clinician. 3. female participants of childbearing potential must be willing to ensure that they or their partner use effective contraception from 1 month prior to first immunisation continuously until 3 months after boost immunisation. see section "contraception and pregnancy" for definition of child-bearing potential and definition of effective contraception. 4. in the investigator's opinion, is able and willing to comply with all trial requirements. 5. willing to allow investigators to discuss the volunteer's medical history with their general practitioner and access all medical records when relevant to study procedures. 6. agreement to refrain from blood donation during the study. 7. participants who have completed homologous primary vaccination with either inactivated or mrna or viral vector covid-19 vaccines (full approval, cma or eua) and is at least 6 months post second vaccination.